---
document_datetime: 2025-09-24 11:06:22
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/avtozma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: avtozma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.8395028
conversion_datetime: 2025-12-23 07:14:25.213639
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Avtozma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthecompleteproductlifecycleprocedures,youmayneedtoalsorefertoEPAR-Proceduralstepstakenandscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amendedon   | Product Information affected3   | Summary   |
|---------------------|---------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| VariationtypeIA_IN/ | Thiswas an application for a group of | 23/09/2025                          |                                           | SmPC,                           |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex Il, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (Eu) No. 712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000297134                     | variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.1I.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.aChange inthenumberofunits (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1Changewithin therangeof the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                |            | Labelling and PL   |                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000287521 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Othervariation-Accepted C.I.z (Type IB) -To update Section 6.6. of theSmPC andStep4of theInstructionfor Use (IFU) in the PL for the pre-filled syringe and pre-filled pen of Avtozma 162 mg solutionforinjection(EU/1/24/1896/007- 012)toamendthetemperaturerangefrom 20°C-25°Cto18°C-28°Cbasedon approved long-term and accelerated stability data.Inaddition，theMAHtookthe opportunity to implement an editorial change toSection4.8oftheSmPCinDEtoinserta number,inalignmentwiththePIinotherEU languages, that was previously removed by accident. | 29/07/2025 | SmPCand PL         | ToupdateSection6.6.of theSmPCandStep 4of the Instruction for Use (IFU) in the PL for the pre- filled syringe and pre-filled pen of Avtozma 162 mg solutionforinjection（EU/1/24/1896/007-012)to amendthetemperaturerangefrom20°C-25°Cto 18°C - 28°C based on approved long-term and accelerated stability data. |
| Variation type IB/ EMA/VR/0000284306  | B.I1.b.5 Change to in-process tests or limits appliedduring themanufactureofthe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/07/2025 |                    |                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                       | finished product -B.II.b.5.z Other changes- Accepted                                                                                                                                                                                                                                                                                                                                                                                                       |            |                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Article 61(3) / EMA/N/0000275336      | - Notification acc. Article 61(3) - Accepted Updateof thelabelling(annexIIIA)todelete PC,SNandNNfromthelabellingsectionof the inner cartons(4P) within the multipack (12P).                                                                                                                                                                                                                                                                                | 10/07/2025 | Labelling              |
| Variation type IB / EMA/VR/0000273930 | This was an application for a group of variations. B.II.f.1.bExtensionoftheshelf lifeof the finishedproduct-B.II.f.1.b.5Extension of theshelf-lifeof abiological/immunological medicinalproductinaccordancewithan approved stability protocol-Accepted B.II.f.1.bExtensionoftheshelflifeofthe finishedproduct-B.II.f.1.b.5Extension of theshelf-lifeofabiological/immunological medicinal product in accordance with an approvedstabilityprotocol-Accepted | 19/06/2025 | SmPC, Labelling and PL |
| Variation type IB/ EMA/VR/0000272244  | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4Extension orintroduction of a re- test period/storage period supported by real time data-Accepted                                                                                                                                                                                                                                                                                                     | 06/06/2025 |                        |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000267171   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted   | 22/05/2025   | N/A   |    |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----|
| Variation typeIB/ EMA/VR/0000266466     | B.II.b.5Change to in-processtestsorlimits applied during the manufacture of the finished product-B.II.b.5.z Other changes- Accepted                             | 22/05/2025   | N/A   |    |
| Article 61(3) / EMA/N/0000255445        | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contactdetailsoflocalrepresentative.                                    | 10/03/2025   |       | PL |